IMMUNOLOGICAL METHODS FOR THE DETECTION OF BENZO[A]PYRENE METABOLITES IN URINE

被引:47
作者
GOMES, M
SANTELLA, RM
机构
[1] COLUMBIA UNIV,SCH PUBL HLTH,CTR CANC,NEW YORK,NY 10032
[2] COLUMBIA UNIV,SCH PUBL HLTH,DIV ENVIRONM SCI,NEW YORK,NY 10032
关键词
D O I
10.1021/tx00016a006
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two monoclonal antibodies (10C10 and 4D5) have been developed from the spleen cells of Balb/c mice immunized with 6-aminobenzo[o]pyrene covalently coupled to bovine serum albumin. These antibodies have been used in an immunoassay for the detection of benzo[a]pyrene and its metabolites in mouse urine. The antibodies were characterized in terms of sensitivity and specificity by competitive enzyme-linked immunosorbent assay (ELISA). With both antibodies, 50% inhibition of antibody binding is at 4 pmol of BP. The antibodies also cross-react with a number of BP metabolites as well as with several other polycyclic aromatic hydrocarbons (PAHs) including pyrene, 1-aminopyrene, and 7,12-dimethylbenz[o]anthracene but with different sensitivities. These results suggest that this assay will detect multiple PAH metabolites in urine. To test the assay on biological samples, mice were treated with [3H]BP, and urine was collected and digested with β-glucuronidase and aryl sulfatase. Several methods were used to isolate BP and its metabolites from the urine, including ethyl acetate extraction, Sep-pak C18 cartridge chromatography, XAD2 resin chromatography, and immunoaffinity chromatography with antibody 4D5. Analysis of the urine extracts with antibody 4D5 gave 50% inhibition at 12-15 pmol of metabolites. Thus, quantitation of metabolites in this sample by competitive ELISA against a standard curve of BP would have underestimated actual metabolite levels by about 70%. This assay will be applied to the analysis of urines from individuals with environmental or occupational exposure. Since humans are usually exposed to BP in complex mixtures of PAHs, multiple metabolites may be present in the urine, making absolute quantitation difficult. This assay should thus serve as a general indicator of exposure to this class of chemicals. © 1990, American Chemical Society. All rights reserved.
引用
收藏
页码:307 / 310
页数:4
相关论文
共 20 条
[1]  
BECKER G, 1983, CANCER LETT, V17, P301
[2]   BIOLOGICAL MONITORING OF HUMAN EXPOSURE TO COAL-TAR - URINARY-EXCRETION OF TOTAL POLYCYCLIC AROMATIC-HYDROCARBONS, 1-HYDROXYPYRENE AND MUTAGENS IN PSORIATIC PATIENTS [J].
CLONFERO, E ;
ZORDAN, M ;
VENIER, P ;
PALEOLOGO, M ;
LEVIS, AG ;
COTTICA, D ;
POZZOLI, L ;
JONGENEELEN, FJ ;
BOS, RP ;
ANZION, RBM .
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 1989, 61 (06) :363-368
[4]  
GROOPMAN JD, 1987, PHARMACOL THERAPEUT, V34, P324
[5]   URINARY 1-HYDROXYPYRENE LEVELS IN WORKERS HANDLING PETROLEUM COKE [J].
JONGENEELEN, FJ ;
ANZION, RBM ;
THEUWS, JLG ;
BOS, RP .
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, 1989, 26 (01) :133-136
[6]   1-HYDROXYPYRENE IN URINE AS A BIOLOGICAL INDICATOR OF EXPOSURE TO POLYCYCLIC AROMATIC-HYDROCARBONS IN SEVERAL WORK ENVIRONMENTS [J].
JONGENEELEN, FJ ;
ANZION, RBM ;
SCHEEPERS, PTJ ;
BOS, RP ;
HENDERSON, PT ;
NIJENHUIS, EH ;
VEENSTRA, SJ ;
BROUNS, RME ;
WINKES, A .
ANNALS OF OCCUPATIONAL HYGIENE, 1988, 32 (01) :35-43
[7]   1-HYDROXYPYRENE IN HUMAN-URINE AFTER EXPOSURE TO COAL-TAR AND A COAL-TAR DERIVED PRODUCT [J].
JONGENEELEN, FJ ;
ANZION, RBM ;
LEIJDEKKERS, CM ;
BOS, RP ;
HENDERSON, PT .
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 1985, 57 (01) :47-55
[8]   BIOLOGICAL MONITORING OF POLYCYCLIC AROMATIC-HYDROCARBONS - METABOLITES IN URINE [J].
JONGENEELEN, FJ ;
BOS, RP ;
ANZION, RBM ;
THEUWS, JLG ;
HENDERSON, PT .
SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH, 1986, 12 (02) :137-143
[9]   EXCRETION OF 3-HYDROXY-BENZO(A)PYRENE AND MUTAGENICITY IN RAT URINE AFTER EXPOSURE TO BENZO(A)PYRENE [J].
JONGENEELEN, FJ ;
LEIJDEKKERS, CM ;
BOS, RP ;
THEUWS, JLG ;
HENDERSON, PT .
JOURNAL OF APPLIED TOXICOLOGY, 1985, 5 (05) :277-282
[10]   RADIOIMMUNOASSAY FOR BENZO[A]PYRENE [J].
KADO, NY ;
WEI, ET .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1978, 61 (01) :221-225